Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related Infection
NCT ID: NCT05251584
Last Updated: 2022-02-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2021-12-01
2023-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis
NCT00751374
Use of Ointments in Prevention of Catheter Related Infections in PD
NCT00400595
Mupirocin 2% Ointment Vs Spray Antibiotics on Temporary Hemodialysis Catheter
NCT05874219
Antimicrobial Photodynamic Therapy in the Nasal Decolonization of Maintenance Hemodialysis Patients
NCT04047914
Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis
NCT03132116
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mupirocin and Gentamicin
2% mupirocin ointments apply at exit-site once daily after wound cleaning before recruit in the study then use 0.1% gentamicin cream apply at exit-site once daily after wound cleaning after entry to the study.
Mupirocin
Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021
Gentamicin
Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mupirocin
Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021
Gentamicin
Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* End stage renal disease patients on peritoneal dialysis follow up at Phramongkutklao hospital's peritoneal dialysis clinic between January 1, 2021 to March 31, 2023
* Start peritoneal dialysis or follow up at Phramongkutklao hospital's peritoneal dialysis clinic at least 90 days before recruited
* Use topical mupirocin ointment for prevention of peritoneal dialysis-related infection between January 1, 2021 to December 31, 2021
* Can be used LINE application throughout the study
Exclusion Criteria
* Previous systemic antibiotics use within 90 days before recruited
* Previous peritoneal dialysis-related infection within 28 days before recruited
* Immunosuppressants used
* Prospective follow up less than 2 months
* Don't sign informed consent
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Silpakorn University
OTHER
Phramongkutklao College of Medicine and Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ittaprach Yimsuk, PharmD
Role: STUDY_CHAIR
College of Pharmacy, Rangsit university
Pamila Tasanavipas, MD
Role: STUDY_DIRECTOR
Phramongkutklao hospital and College of Medicine
Daraporn Rungprai, BCP
Role: STUDY_DIRECTOR
Faculty of Pharmacy, Silpakorn University
Wichai Santimaleeworagun, BCP
Role: STUDY_DIRECTOR
Faculty of Pharmacy, Silpakorn University
Kulthida Chaijumroen, B.N.S.
Role: PRINCIPAL_INVESTIGATOR
Phramongkutklao hospital and College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phramongkutklao Hospital
Ratchathewi, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PDRI-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.